Trials / Completed
CompletedNCT03264703
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
An Observational Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus Anti-TNF Versus cDMARDs in Real World ["HUMAN" Study]
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 212 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to observe the disease activity change of Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARD) plus anti-tumour necrosis factor (anti-TNF) from baseline to 6 months compared with cDMARDs, as measured by the disease activity score with the erythrocyte sedimentation rate (DAS28-ESR).
Conditions
Timeline
- Start date
- 2017-09-11
- Primary completion
- 2019-07-17
- Completion
- 2019-07-17
- First posted
- 2017-08-29
- Last updated
- 2020-12-16
Locations
15 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03264703. Inclusion in this directory is not an endorsement.